Home  >  News
 Eppen_DNALoBind_Jun24
you can get e-magazine links on WhatsApp. Click here
News
+ Font Resize -

Regeneron’s phase 2 trial of high-dose aflibercept in wet age-related macular degeneration meets primary endpoint

Tarrytown, New York
Wednesday, August 25, 2021, 15:00 Hrs  [IST]

Regeneron Pharmaceuticals, Inc. announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients with wet age-related macular degeneration (wet AMD).

In this small trial involving 106 patients, a higher proportion of patients in the aflibercept 8 mg group had no retinal fluid (43.4%, n=23/53) compared to patients treated with Eylea 2 mg (26.4%, n=14/53) (p=0.067) at week 16, the primary efficacy endpoint. At this timepoint patients had received three initial doses (administered at weeks 0, 4 and 8), after which dosing was extended.

Aflibercept 8 mg is currently being evaluated in two large phase 3 trials in wet AMD and diabetic macular edema (DME), which are expected to report results in the second half of 2022. The trials will assess the safety and efficacy of aflibercept 8 mg for up to two years, with visual acuity as the primary efficacy endpoint at 48 weeks, measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA). Both trials will assess aflibercept 8 mg compared to Eylea 2 mg, testing dosing intervals of every 12 weeks and every 16 weeks.

"We are cautiously optimistic that these early data suggest that a higher dose of aflibercept may potentially benefit patients with wet AMD, and we look forward to phase 3 data next year, which will be crucial to understand its overall efficacy and safety," said George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer of Regeneron. "Having worked for nearly two decades in retinal disease, we know that large, robust data sets are required to fully understand whether a medicine can achieve three critical things: improved visual and anatomic outcomes, convenient dosing, and a safety profile that is consistent with Eylea."

During the initial 16 weeks of the phase 2 trial, adverse events (AEs) in the study eye occurred in 17.0% (9 of 53) of aflibercept 8 mg patients and 22.6% (12 of 53) of Eylea 2 mg patients. Serious ocular AEs occurred in two patients overall, one in the aflibercept 8 mg group (retinal tear) and one in the Eylea 2 mg group (visual acuity reduced). There were no AEs of intraocular inflammation (including occlusive retinal vasculitis), anti-platelet trialists' collaboration (APTC)-defined arterial thromboembolic events or deaths in either patient group.

Wet AMD is the leading cause of vision loss among people 50 years and older in the US Existing anti-VEGF treatments including Eylea have helped change the course of disease for millions of patients worldwide, and efforts to develop new medicines are focused on further enhancing clinical effectiveness while extending the time between treatment doses. This new, concentrated high-dose aflibercept formulation enables a greater amount of medicine to be administered with each treatment, potentially extending the time between doses while retaining the efficacy and safety profile seen with Eylea 2 mg.

Aflibercept 8 mg is being jointly developed by Regeneron and Bayer.

The phase 2 randomized, single-masked trial (NCT04126317) enrolled 106 treatment-naïve patients with wet AMD. The trial was designed to investigate the safety, efficacy and tolerability of high-dose aflibercept (8 mg) compared to the existing approved dose of Eylea (2 mg). Patients were randomized into two groups, with one group receiving aflibercept 8 mg (n=53) and the other group receiving Eylea 2 mg (n=53). Patients in both groups received three initial injections (weeks 0, 4 and 8), before the primary endpoint was assessed at week 16, after which dosing was extended to every 12 weeks, or more frequently if required due to persistent or worsening disease. Efficacy was assessed via the presence of retinal fluid in the center subfield on optical coherence tomography (OCT) at this timepoint. The trial will continue through week 44.

Trial participants were at least 50 years of age (mean: 77 years), baseline retinal thickness was 502.1 microns, and the BCVA ETDRS letter score was between 24 to 78 in the study eye (mean: 59 letters).

There are two ongoing pivotal trials to investigate the efficacy and safety of aflibercept 8 mg versus Eylea 2 mg. In DME, Regeneron is sponsoring the phase 2/3 multi-center, randomized, double-masked PHOTON trial (NCT04429503). In wet AMD, Bayer is sponsoring the Phase 3 multi-center, randomized, double-masked PULSAR trial (NCT04423718) in treatment naïve patients. Across both trials, patients are randomized into one of three treatment groups, testing aflibercept 8 mg with dosing regimens at either 12- or 16-week intervals or Eylea 2 mg with an 8-week dosing regimen.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

 
Follow on LinkedIn
Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CPHISEA24
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram